IMmunotherapy: Prospective Assessment of Cannabis Treatment in Cancer

Part of paid clinical trials in Portland, Oregon.

Sponsor
State University of New York at Buffalo
Study ID
NCT06206941
Status
Recruiting
Apply to this trial

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
21 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The purpose of this research is to assess how patients with cancer being treated with Immune Checkpoint Inhibitors (ICI) manage symptoms related to cancer and/or its treatment. Patients use a variety of ways to manage symptoms including traditional and alternative treatments including cannabis, acupuncture, etc. This research will have an important impact on our knowledge of cancer symptom management, and ultimately improve patient care and safety. Participants will complete online surveys and 7 days of ecological momentary assessments at 0, 1, 2, 4, 6, 9 and 12 month to compare the cannabis users and non cannabis users symptoms.

Key Dates

Start date
Jan 2, 2025
Status verified
Oct 2025
Primary completion
Sep 30, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
450 participants (estimated)

Arms

  • Arm: Cannabis User
    Cancer patients being treated with immunotherapy and using cannabis
  • Arm: Cannabis non-user
    Cancer patients being treated with immunotherapy and not using cannabis

Primary Outcome Measure

Patient Reported Outcomes Measurement Information System: Pain interference [ Time Frame: 0,1,2,4,6,9 and 12 months ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Oregon Health and Science UniversityPortlandOregon97239
Shannon Nugent, PhD
[email protected]
503-220-8262
Felipe Rubim, MS
[email protected]
503-220-8262
Thomas Jefferson UniversityPhiladelphiaPennsylvania19107
Brooke Worster, MD
[email protected]
215-955-1888

Find similar trials in Portland, OR

By research site
Oregon Health and Science University· Portland, ORThomas Jefferson University· Philadelphia, PA

Related Studies